Generalised uridine diphosphate galactose-4-epimerase deficiency

J H Walter, R E P Roberts, G T N Besley, J E Wraith, M A Cleary, J B Holton, R MacFaul

Abstract
The generalised form of epimerase deficiency galactosaemia has been described in only two children from unrelated families. Their progress is reported and three other affected children from these families are described. The initial presentation was similar to classic galactosaemia. Despite treatment all have shown poor growth and moderate learning difficulties. Three have sensorineural deafness and four have pronounced dysmorphic features. The two older female patients have normal pubertal development.

Keywords: UDP galactose-4-epimerase deficiency; galactosaemia; transferrin isoelectric focusing

GALACTOSAEMIA is caused by inherited deficiencies of one of three enzymes involved in the metabolism of galactose: galactose-1-phosphate uridylyltransferase (GALT), galactokinase (GALK), and uridine diphosphate galactose-4-epimerase (GALE). GALE deficiency confined to red cells is benign. A generalised form has only been reported previously in two patients from unrelated families.1,3 We report the progress of these children and describe three further cases from these two families.

Case reports
Both families are of Asian origin and highly consanguineous but are not known to be related one to the other. Details of the children's clinical presentation, investigations, and progress are given in Table 1. All patients had raised concentrations of galactose-1-phosphate (gal-1-P) at diagnosis, normal GALT; but undetectable GALE activity in red cells, confirming the diagnosis of GALE deficiency (see table 1 for details). The diagnosis of generalised, rather than peripheral, deficiency was established by the lack of detectable enzyme in cultured skin fibroblasts from patients 1 and 3 and in cultured amniocytes from patient 2; the same diagnosis was assumed for patients 4 and 5.

All children were born at term following uneventful pregnancies. The index cases for each family (patients 1 and 3) presented with a clinical illness similar to that seen in classic galactosaemia (GALT deficiency) with poor feeding, weight loss, and evidence of liver and renal tubular disease. These were corrected by

Table 1 Patients' details

<table>
<thead>
<tr>
<th>Year of birth</th>
<th>Neonatal presentation</th>
<th>Initial investigations</th>
<th>GALE activity</th>
<th>Dyssomorphic features</th>
<th>Progress</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient 1</td>
<td>Jaundice, weight loss, hypotonia, vomiting</td>
<td>RBC: 0.1 µmol/ml red cells/h (controls, 3.0–6.2); fibroblasts: undetectable; liver tissue: &gt; 97% centile, posteriorly rotated ears and a short philtrum; no hand deformities and no micrognathia</td>
<td>Facial dysmorphism with inner canthus distance below third centile, palpebral fissure length 0.75–3.05</td>
<td>Persistent hyponatonia with developmental delay; severe sensorineural deafness; global oto-mandibulo-facial dysplasia; normal pubertal development</td>
<td>Persistent hyponatonia with developmental delay; severe sensorineural deafness; global oto-mandibulo-facial dysplasia; normal pubertal development</td>
</tr>
<tr>
<td>Patient 2</td>
<td>No clinical illness (treated from birth)</td>
<td>Cultured amniocytes: &lt; 5% of controls</td>
<td>Not dysmorphic</td>
<td>Moderate learning disability; short stature; no sensorineural deafness</td>
<td>Moderate learning disability; short stature; no sensorineural deafness</td>
</tr>
<tr>
<td>Patient 3</td>
<td>Poor feeding, irritability, jaundice, hepatomegaly, cataracts</td>
<td>Raised liver transaminases; raised blood methionine; RBC: undetectable</td>
<td>Ligamentous laxity, micrognathia, posteriorly rotated ears, persistent femoral anteversion, internal tibial torsion, short stature (with normal bone age)</td>
<td>Severe sensorineural hearing loss; moderate learning difficulties; normal pubertal development</td>
<td>Severe sensorineural hearing loss; moderate learning difficulties; normal pubertal development</td>
</tr>
<tr>
<td>Patient 4</td>
<td>Hypotonia, poor feeding</td>
<td>RBC: undetectable</td>
<td>Micrognathia, high palate, pigeon chest, flexion deformities of the proximal and middle third, fourth, and fifth fingers, dislocatable left hip, positional talipes and joint laxity, short stature</td>
<td>Tracheostomy for upper airways obstruction at 3 months; no sensorineural deafness; poor feeding, moderate developmental delay with more profound delayed gross motor skills</td>
<td>Tracheostomy for upper airways obstruction at 3 months; no sensorineural deafness; poor feeding, moderate developmental delay with more profound delayed gross motor skills</td>
</tr>
</tbody>
</table>

RBC, red blood cell; gal-1-P, galactose-1-phosphate; GALE, uridine diphosphate galactose-4-epimerase.
withdrawing lactose from their diet. The other patients were diagnosed and commenced treatment before they developed noticeable illness. However, hypotonia has been a consistent finding in the newborn period in all the children and has persisted throughout infancy and into childhood despite treatment. Patients 1, 3, 4, and 5 are dysmorphic (table 1).

In patients 4 and 5, we analysed serum transferrin by immunofixation and Coomassie brilliant blue staining following isoelectric focusing (pH range, 4.0–6.0). The pattern was abnormal at diagnosis but became normal within a few days in parallel with the fall in the concentrations of galactose-1-phosphate after the start of treatment. The abnormal pattern was identical to that seen in patients with type 1 carbohydrate deficient glycoprotein syndrome, with apparent increased concentrations of disialotransferrins and asialotransferrins.

All patients are short, despite satisfactory intrauterine growth. An arginine stimulation test produced a normal increase in growth hormone in patient 3. Thyroid function was normal in all patients. All have developmental delay and learning difficulties. Patients 1, 3, and 5 have sensorineural deafness, but not patients 2 and 4. In contrast to classic galactosaemia, the two older female patients are showing normal pubertal development with appropriate follicle stimulating hormone (FSH), luteinising hormone (LH), and oestriadiol values. Red blood cell gal-1-P concentrations have remained raised in the children but are lower than those seen in patients with classic galactosaemia while on treatment.

Discussion

Generalised GALE deficiency appears to be an exceptionally rare disorder. We are unaware of any other patients, although one patient reported initially to have this disorder was later confirmed as having GALT deficiency rather than epimerase deficiency. Both the families described here are highly consanguineous with first cousin marriages over many generations. In such families there may be more than one recessive disorder affecting individual members. Consequently, it is difficult to determine which features are caused by epimerase deficiency. For example in pedigree B, a further cousin, who did not have epimerase deficiency, had some dysmorphic features similar to patients 4 and 5. The only consistent findings are failure to thrive with a very poor growth rate and learning difficulties.

Treatment for children with generalised GALE deficiency, as with GALT deficiency, is by restriction of dietary galactose. Galactose is an essential component of galactoproteins and galactolipids. In GALT deficiency there is considerable endogenous production of galactose and production of UDP-galactose by reversal of the pyrophosphorylase pathway. Theoretically, in generalised GALE deficiency, no such endogenous production of galactose is possible, with a resulting deficiency in galactolipid and galactoprotein production. Abnormal forms of the low density lipoprotein receptor, a glycoprotein, are synthesised by mutant hamster cells with a complete deficiency of GALE activity. However, fibroblasts from patient 1 have been shown to synthesise receptors of normal size and activity suggesting that glycoprotein production is sufficient, presumably as a result of some residual GALE activity in the liver.

Therefore, it might be unnecessary to provide patients with any dietary galactose. All our patients have been treated with a galactose restricted diet with a small amount of lactose added to allow the production of essential glycoproteins and glycolipids. The additional lactose has been discontinued in patients 1 and 2 without any obvious detrimental effect.

The abnormalities on transferrin isoelectric focusing also suggest underlying defects in glycosylation, which are corrected by dietary treatment. Whether this is a result of increased concentrations of galactose-1-phosphate or UDP-galactose, or some other mechanism, is not clear at this stage. Similar cathodal shifts in transferrins have been observed in untreated patients with classic galactosaemia as well as hereditary fructose intolerance, and evidence suggests that these secondary changes may reflect inhibition of key enzymes involved with N-glycosylation.

Recently, the human GALE gene has been cloned and the full length cDNA characterised. Mutations responsible for the peripheral form of GALE deficiency have been reported. Mutation analysis has been undertaken recently in patients 1, 4, and 5. All three children were found to be homozygous for the same mutation (V94M), the product of which galactosyltransferase, with a resulting deficiency in galactolipid formation. In patients 4 and 5, we analysed serum transferrins by immunofixation and Coomassie brilliant blue staining following isoelectric focusing (pH range, 4.0–6.0). The pattern was abnormal at diagnosis but became normal within a few days in parallel with the fall in the concentrations of galactose-1-phosphate after the start of treatment. The abnormal pattern was identical to that seen in patients with type 1 carbohydrate deficient glycoprotein syndrome, with apparent increased concentrations of disialotransferrins and asialotransferrins.

All patients are short, despite satisfactory intrauterine growth. An arginine stimulation test produced a normal increase in growth hormone in patient 3. Thyroid function was normal in all patients. All have developmental delay and learning difficulties. Patients 1, 3, and 5 have sensorineural deafness, but not patients 2 and 4. In contrast to classic galactosaemia, the two older female patients are showing normal pubertal development with appropriate follicle stimulating hormone (FSH), luteinising hormone (LH), and oestriadiol values. Red blood cell gal-1-P concentrations have remained raised in the children but are lower than those seen in patients with classic galactosaemia while on treatment.

Discussion

Generalised GALE deficiency appears to be an exceptionally rare disorder. We are unaware of any other patients, although one patient reported initially to have this disorder was later confirmed as having GALT deficiency rather than epimerase deficiency. Both the families described here are highly consanguineous with first cousin marriages over many generations. In such families there may be more than one recessive disorder affecting individual members. Consequently, it is difficult to determine which features are caused by epimerase deficiency. For example in pedigree B, a further cousin, who did not have epimerase deficiency, had some dysmorphic features similar to patients 4 and 5. The only consistent findings are failure to thrive with a very poor growth rate and learning difficulties.

Treatment for children with generalised GALE deficiency, as with GALT deficiency, is by restriction of dietary galactose. Galactose is an essential component of galactoproteins and galactolipids. In GALT deficiency there is considerable endogenous production of galactose and production of UDP-galactose by reversal of the pyrophosphorylase pathway. Theoretically, in generalised GALE deficiency, no such endogenous production of galactose is possible, with a resulting deficiency in galactolipid and galactoprotein production. Abnormal forms of the low density lipoprotein receptor, a glycoprotein, are synthesised by mutant hamster cells with a complete deficiency of GALE activity. However, fibroblasts from patient 1 have been shown to synthesise receptors of normal size and activity suggesting that glycoprotein production is sufficient, presumably as a result of some residual GALE activity in the liver. Therefore, it might be unnecessary to provide patients with any dietary galactose. All our patients have been treated with a galactose restricted diet with a small amount of lactose added to allow the production of essential glycoproteins and glycolipids. The additional lactose has been discontinued in patients 1 and 2 without any obvious detrimental effect.

The abnormalities on transferrin isoelectric focusing also suggest underlying defects in glycosylation, which are corrected by dietary treatment. Whether this is a result of increased concentrations of galactose-1-phosphate or UDP-galactose, or some other mechanism, is not clear at this stage. Similar cathodal shifts in transferrins have been observed in untreated patients with classic galactosaemia as well as hereditary fructose intolerance, and evidence suggests that these secondary changes may reflect inhibition of key enzymes involved with N-glycosylation.

Recently, the human GALE gene has been cloned and the full length cDNA characterised. Mutations responsible for the peripheral form of GALE deficiency have been reported. Mutation analysis has been undertaken recently in patients 1, 4, and 5. All three children were found to be homozygous for the same mutation (V94M), the product of which...
Xylitol and acute otitis media

Xylitol is used as an artificial sweetener and its use prevents dental caries, not only by replacing sucrose but also by inhibiting *Streptococcus mutans*. Paediatricians in Finland found that xylitol also inhibited the growth of pneumococci, and in a 1996 *BMJ* paper they showed that xylitol chewing gum reduced the occurrence of otitis media in children old enough to chew it. Now they have compared xylitol syrup, lozenges, and gum with placebos in younger children (Matti Uhari and colleagues. *Pediatrics* 1998;102:879–84).

The study included 857 healthy children aged from 7 months to 7 years attending day care centres. Those old enough to chew safely were randomly assigned to xylitol or placebo, chewing gum or lozenges. The younger ones were randomised to xylitol or placebo syrup. Over a trial period of three months the incidence of acute otitis media was reduced by 30% with xylitol syrup, by 40% with chewing gum, and by 20% with lozenges, compared with the placebo groups. There were similar reductions in the use of antibiotics.

Commentators (Ibid: 971–2 and 974–5) caution against rushing into the widespread administration of xylitol to children. Their reasons are both theoretical (the dose needed for young children could cause gastrointestinal upset, its safety is not established, and the long term effectiveness is uncertain) and pragmatic (the minimal effective dose is not known (it was given five times daily in the trial) and there are no suitable preparations available in the USA). The way in which xylitol produces this effect is far from clear. An antipneumococcal action does not seem to be a full explanation.

It seems unlikely that xylitol treatment of all children will be either practicable or desirable but further work could show it to be beneficial for those with recurrent acute otitis media. The associated decrease in antibiotic use is attractive in view of present concerns about antibiotic resistance.